1.
Jommi C, Cavazza M. Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals. GRHTA [Internet]. 17Jul.2019 [cited 2Apr.2020];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/460